Skip to content

Biodesix, Inc. BDSX Inventory write-downs

Inventory write-downs at other companies

Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
-$10K+90.1%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$1.49M-78.0%

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Reported directly by Biodesix, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryWriteDown.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s inventory write-downs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s inventory write-downs?
Biodesix, Inc. (BDSX) reported inventory write-downs of $20K in Q1 2026.
What does inventory write-downs mean?
This represents the non-cash charge taken to reduce the carrying value of inventory when its market value falls below its cost due to obsolescence, damage, or declining demand. Frequent or large write-downs can indicate inefficiencies in inventory management or potential issues with product marketability. It serves as a key indicator of operational health and inventory turnover effectiveness.